Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ARE THERE ANY ARGUMENTS TO PROSCRIBE HORM ONE REPLACEMENT THERAPY IN WOMEN TREATED FOR OVARIAN ADENOCARCINOMA
Autore:
LHOMME C; DELALOGE S; GONCALVES E; TALEA V; PAUTIER P;
Indirizzi:
INST GUSTAVE ROUSSY,CONSULTAT GYNECOL MED,39 RUE CAMILLE DESMOULINS F-94805 VILLEJUIF FRANCE
Titolo Testata:
Bulletin du cancer
fascicolo: 10, volume: 84, anno: 1997,
pagine: 981 - 986
SICI:
0007-4551(1997)84:10<981:ATAATP>2.0.ZU;2-K
Fonte:
ISI
Lingua:
FRE
Soggetto:
ORAL-CONTRACEPTIVE USE; RISK-FACTORS; PROGESTERONE-RECEPTOR; ESTROGEN USE; CANCER RISK; GROWTH; RESPONSIVENESS; EXPRESSION; INHIBITION; OVULATION;
Keywords:
OVARIAN ADENOCARCINOMA; HORMONE REPLACEMENT THERAPY; MENOPAUSE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
42
Recensione:
Indirizzi per estratti:
Citazione:
C. Lhomme et al., "ARE THERE ANY ARGUMENTS TO PROSCRIBE HORM ONE REPLACEMENT THERAPY IN WOMEN TREATED FOR OVARIAN ADENOCARCINOMA", Bulletin du cancer, 84(10), 1997, pp. 981-986

Abstract

The hormonal status of 95% of the women treated for epithelial ovarian carcinoma is menopausal either naturally or after treatment This raises the important question of the hormonal replacement therapy (HRT) among these patients. Several retrospective studies have explored the potentiel positive or negative influence of HRT on the genesis of ovarian adenocarcinoma. Although somehow contradictory, these studies takenall together fail to show any favouring nor protective role of HRT. In vitro, estrogens have been shown to induce the proliferation of ovarian cancer cell lines. On the opposite, progesterone and antiestrogenshave antiproliferative effects. Both types of effects are mediated byintracellular steroid hormone receptors (ER, PgR). Although high doseprogesterone derivatives and antiestrogens have been shown to obtain therapeutic responses in patients carrying advanced ovarian carcinoma,response rates were usually less than 20%, and no clinico-biological correlation (with ER, PgR status) could be demonstrated. There is therefore no evidence for a clinical significance of the presence of hormonal receptors in these tumors. A single retrospective study explored the possible influence of HRT on the prognosis of patients treated for ovarian carcinoma, and did not demonstrate any deleterious effect. This review of recent epidemiological, biological and clinical data failsto find any argument against the prescription of HRT in patients treated for ovarian adenocarcinoma, in the absence of other contra-indications.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 18:00:39